soligenix, inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous t-cell lymphoma, oral mucositis, pediatric crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.
![Soligenix logo](/files/LOGO/812796-SNGX.png)
Company profile
Ticker
SNGX
Exchange
Website
CEO
Christopher Schaber
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
DOR BIOPHARMA INC, ENDOREX CORP, IMMUNOTHERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
Enteron Pharmaceuticals, Inc. • Orasomal Technologies Inc. • Soligenix BioPharma Canada Incorporated • Soligenix UK Limited • Soligenix NE B.V. • Soligenix Biopharma HI, Inc. ...
IRS number
411505029
SNGX stock data
Latest filings (excl ownership)
S-1/A
IPO registration (amended)
15 Mar 24
10-K
2023 FY
Annual report
15 Mar 24
S-1
IPO registration
12 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Dec 23
EFFECT
Notice of effectiveness
18 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
15 Dec 23
CORRESP
Correspondence with SEC
14 Dec 23
S-3/A
Shelf registration (amended)
8 Dec 23
CORRESP
Correspondence with SEC
6 Dec 23
CORRESP
Correspondence with SEC
30 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.30 mm | 10.30 mm | 10.30 mm | 10.30 mm | 10.30 mm | 10.30 mm |
Cash burn (monthly) | 954.14 k | 547.26 k | 593.02 k | 780.85 k | 895.44 k | 866.92 k |
Cash used (since last report) | 5.68 mm | 3.26 mm | 3.53 mm | 4.65 mm | 5.33 mm | 5.16 mm |
Cash remaining | 4.62 mm | 7.04 mm | 6.77 mm | 5.65 mm | 4.97 mm | 5.14 mm |
Runway (months of cash) | 4.8 | 12.9 | 11.4 | 7.2 | 5.5 | 5.9 |
Institutional ownership, Q2 2023
20.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 21 |
Opened positions | 5 |
Closed positions | 1 |
Increased positions | 2 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 990.43 mm |
Total shares | 2.12 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Sabby Management | 814.25 k | $573.07 mm |
Altamont Phamaceutical | 678.34 k | $1.05 mm |
Anson Funds Management | 514.14 k | $361.86 mm |
Vanguard | 26.77 k | $18.84 mm |
First Wilshire Securities Management | 23.33 k | $16.00 k |
Geode Capital Management | 20.92 k | $14.53 mm |
VIRT Virtu Financial | 14.14 k | $10.00 k |
Warberg Asset Management | 10.00 k | $7.04 mm |
Tower Research Capital | 6.89 k | $4.85 mm |
Plante Moran Financial Advisors | 4.78 k | $3.36 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Dec 23 | Lapointe Anthony Gregg | Stock Option Common Stock | Grant | Acquire A | No | No | 0.59 | 38,136 | 22.50 k | 38,136 |
15 Dec 23 | Zeldis Jerome B | Stock Option Common Stock | Grant | Acquire A | No | No | 0.59 | 38,136 | 22.50 k | 38,136 |
15 Dec 23 | Parks Diane L. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.59 | 38,136 | 22.50 k | 38,136 |
15 Dec 23 | Rubin Robert J. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.59 | 38,136 | 22.50 k | 38,136 |
8 Dec 23 | Christopher J Schaber | Option Common Stock | Grant | Acquire A | No | No | 0.67 | 150,000 | 100.50 k | 150,000 |
News
Recap: Soligenix Q4 Earnings
15 Mar 24
Soligenix FY GAAP EPS $(0.79) Beats $(0.82) Estimate, Sales $800.00K Beat $797.50K Estimate
15 Mar 24
Soligenix, University Of Hawaii Filed U.S. Patent Application #20240009297: Antibody/adjuvant Compositions And Methods Of Immune Response Generation Against Coronaviruses
11 Jan 24
Why Juniper Networks Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket
9 Jan 24
12 Health Care Stocks Moving In Monday's After-Market Session
8 Jan 24
Press releases
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
15 Mar 24
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
8 Feb 24
Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
26 Jan 24
Soligenix to Present at The Microcap Conference
25 Jan 24
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
8 Jan 24